News Releases

All Releases
View Summary OncoGenex Announces Apatorsen Phase 2 Borealis-2 Trial Continues Following Successful Completion of Futility Analysis
Dec 9, 2015
PDF 14.1 KB Add to Briefcase
View Summary OncoGenex Announces Phase 3 AFFINITY Trial with Custirsen Continues Following Interim Analyses
Dec 1, 2015
PDF 61.2 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2015
Nov 12, 2015
PDF 21.9 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference
Nov 5, 2015
PDF 10.7 KB Add to Briefcase
View Summary OncoGenex to Report Third Quarter 2015 Financial Results on November 12, 2015
Oct 29, 2015
PDF 10.7 KB Add to Briefcase
View Summary OncoGenex Announces EMA Support for Phase 3 AFFINITY Trial Protocol Amendment
Oct 8, 2015
PDF 62.2 KB Add to Briefcase
View Summary OncoGenex Announces Completion of Patient Enrollment in Borealis-2™ Clinical Trial Evaluating Apatorsen in Relapsed or Refractory Metastatic Bladder Cancer
Sep 30, 2015
PDF 16.1 KB Add to Briefcase
View Summary OncoGenex Presents Additional Phase 3 SYNERGY Analyses Showing Custirsen Significantly Reduced Serum Clusterin Levels in Metastatic Prostate Cancer Patients; Low Levels Correlate with Improved Survival in Those at Increased Risk for Poor Outcomes
Sep 28, 2015
PDF 19.6 KB Add to Briefcase
View Summary OncoGenex Announces Phase 2 Rainier Results in Previously Untreated Metastatic Pancreatic Cancer
Sep 23, 2015
PDF 14.3 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2015
Aug 13, 2015
PDF 21.1 KB Add to Briefcase
View Summary OncoGenex to Report Second Quarter 2015 Financial Results on August 13, 2015
Jul 30, 2015
PDF 10.7 KB Add to Briefcase
View Summary OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Continues Following Completion of Final Futility Survival Analysis
Jul 13, 2015
PDF 14.6 KB Add to Briefcase
View Summary FDA Agrees with OncoGenex' Phase 3 AFFINITY Protocol Amendment
Jun 10, 2015
PDF 63.0 KB Add to Briefcase
View Summary OncoGenex Announces Data from Borealis-1™ Trial Showing Clinical Benefit with Apatorsen in Metastatic Bladder Cancer
Jun 1, 2015
PDF 66.8 KB Add to Briefcase
View Summary OncoGenex Announces Data from the Phase 3 SYNERGY Trial Showing a Survival Benefit with Custirsen in Patients with Poor Prognosis
May 30, 2015
PDF 17.8 KB Add to Briefcase
View Summary OncoGenex Announces Data to be Presented at ASCO 2015 Annual Meeting
May 20, 2015
PDF 15.6 KB Add to Briefcase
View Summary OncoGenex Pharmaceuticals, Inc. Reports Financial Results for First Quarter 2015
May 14, 2015
PDF 20.2 KB Add to Briefcase
View Summary OncoGenex to Report First Quarter 2015 Financial Results on May 14, 2015
May 4, 2015
PDF 10.7 KB Add to Briefcase
View Summary OncoGenex Announces Share Purchase Agreement with Lincoln Park Capital Fund, LLC
Apr 30, 2015
PDF 10.5 KB Add to Briefcase
View Summary OncoGenex Announces Custirsen Phase 3 "ENSPIRIT" Trial Update
Apr 30, 2015
PDF 16.3 KB Add to Briefcase
Showing 21-40 of 385 Page: 1 2 3 4 5 6 ... 20  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase